158 related articles for article (PubMed ID: 23914578)
21. Melanotan and the posterior reversible encephalopathy syndrome.
Kaski D; Stafford N; Mehta A; Jenkins IH; Malhotra P
Ann Intern Med; 2013 May; 158(9):707-8. PubMed ID: 23648958
[No Abstract] [Full Text] [Related]
22. Dermatoscopic differences between atypical melanocytic naevi and thin malignant melanomas.
Fikrle T; Pizinger K
Melanoma Res; 2006 Feb; 16(1):45-50. PubMed ID: 16432455
[TBL] [Abstract][Full Text] [Related]
23. Consider underlying body dysmorphic disorder in users of melanotan.
Affleck A
Br J Dermatol; 2010 Feb; 162(2):459-60. PubMed ID: 19919633
[No Abstract] [Full Text] [Related]
24. [Dermoscopic changes in melanocytic nevi during use of melanotan II].
Mang R; Krahl D; Assmann T
Hautarzt; 2012 Nov; 63(11):880-4. PubMed ID: 23052015
[TBL] [Abstract][Full Text] [Related]
25. Surveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy.
Bauer J; Blum A; Strohhäcker U; Garbe C
Br J Dermatol; 2005 Jan; 152(1):87-92. PubMed ID: 15656806
[TBL] [Abstract][Full Text] [Related]
26. [Melanotan].
Mahiques-Santos L
Actas Dermosifiliogr; 2012 May; 103(4):257-9. PubMed ID: 22051769
[No Abstract] [Full Text] [Related]
27. Age-related prevalence of dermoscopy patterns in acquired melanocytic naevi.
Zalaudek I; Grinschgl S; Argenziano G; Marghoob AA; Blum A; Richtig E; Wolf IH; Fink-Puches R; Kerl H; Soyer HP; Hofmann-Wellenhof R
Br J Dermatol; 2006 Feb; 154(2):299-304. PubMed ID: 16433800
[TBL] [Abstract][Full Text] [Related]
28. Changes in the dermoscopic appearance of melanocytic naevi after photochemotherapy or narrow-band ultraviolet B phototherapy.
Kilinc Karaarslan I; Teban L; Dawid M; Tanew A; Kittler H
J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):526-31. PubMed ID: 17373982
[TBL] [Abstract][Full Text] [Related]
29. Eruptive Melanocytic Nevi: A Review.
Burian EA; Jemec GBE
Am J Clin Dermatol; 2019 Oct; 20(5):669-682. PubMed ID: 31119650
[TBL] [Abstract][Full Text] [Related]
30. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.
Gilhooley E; Daly S; McKenna D
Dermatology; 2021; 237(6):995-999. PubMed ID: 34464955
[TBL] [Abstract][Full Text] [Related]
31. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers.
Dorr RT; Ertl G; Levine N; Brooks C; Bangert JL; Powell MB; Humphrey S; Alberts DS
Arch Dermatol; 2004 Jul; 140(7):827-35. PubMed ID: 15262693
[TBL] [Abstract][Full Text] [Related]
32. Melanotan II: a possible cause of renal infarction: review of the literature and case report.
Peters B; Hadimeri H; Wahlberg R; Afghahi H
CEN Case Rep; 2020 May; 9(2):159-161. PubMed ID: 31953620
[TBL] [Abstract][Full Text] [Related]
33. [Melanoma and dysplastic nevus after 8 years of topical Caryolysine].
Cosnes A; Revuz J; Wechsler J; Touraine R
Ann Dermatol Venereol; 1984; 111(2):127-32. PubMed ID: 6721359
[TBL] [Abstract][Full Text] [Related]
34. Melanotan-induced priapism: a hard-earned tan.
Dreyer BA; Amer T; Fraser M
BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30796078
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
Dorr RT; Lines R; Levine N; Brooks C; Xiang L; Hruby VJ; Hadley ME
Life Sci; 1996; 58(20):1777-84. PubMed ID: 8637402
[TBL] [Abstract][Full Text] [Related]
36. Use of melanotan I and II in the general population.
Evans-Brown M; Dawson RT; Chandler M; McVeigh J
BMJ; 2009 Feb; 338():b566. PubMed ID: 19224885
[No Abstract] [Full Text] [Related]
37. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet.
Breindahl T; Evans-Brown M; Hindersson P; McVeigh J; Bellis M; Stensballe A; Kimergård A
Drug Test Anal; 2015 Feb; 7(2):164-72. PubMed ID: 24771717
[TBL] [Abstract][Full Text] [Related]
38. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans.
Dorr RT; Dvorakova K; Brooks C; Lines R; Levine N; Schram K; Miketova P; Hruby V; Alberts DS
Photochem Photobiol; 2000 Oct; 72(4):526-32. PubMed ID: 11045725
[TBL] [Abstract][Full Text] [Related]
39. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals.
Bovenschen HJ; Tjioe M; Vermaat H; de Hoop D; Witteman BM; Janssens RW; Stoof TJ; van de Kerkhof PC
Br J Dermatol; 2006 May; 154(5):880-4. PubMed ID: 16634890
[TBL] [Abstract][Full Text] [Related]
40. Skin surveillance of a U.K. paediatric transplant population.
Thomson MA; Suggett NR; Nightingale PG; Milford DV; Baumann U; Kelly DA; Moss C; Hill VA
Br J Dermatol; 2007 Jan; 156(1):45-50. PubMed ID: 17199565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
